Zhejiang Anglikang Pharmaceutical Co., Ltd. owns Zhejiang Anglikang Capsule Co., Ltd., Zhejiang Anglitai Pharmaceutical Co., Ltd., Jiangsu Yuexin Pharmaceutical Co., Ltd., Zhejiang Anglikang Bioengineering Co., Ltd., Zhejiang Kangyun Huapeng Pharmaceutical Co., Ltd., Zhejiang Anglikang Pharmaceutical Co., Ltd. Sales Co., Ltd. has six holding subsidiaries.

The company insists on quality as the cornerstone of enterprise development and has established a complete quality management system, covering the entire process from product research and development, raw and auxiliary material procurement, production and quality control, warehousing, product issuance to sales tracking, and has been formulated in accordance with GMP specifications. The company's internal control quality standards that are higher than the national statutory standards to ensure product quality.
The company insists on R&D innovation as the driving force for enterprise development. As a national high-tech enterprise, relying on the Zhejiang Key Enterprise Research Institute, provincial enterprise technology center, academician and expert workstation, foreign expert workstation and postdoctoral workstation, it continues to promote independent research and development. At present, a large number of core technologies have been successfully accumulated and an excellent R&D team with various professional talents has laid a rich foundation for the company to realize independent drug research and development, and to achieve a leap from imitation to imitation and creation, from imitation to innovation.

The company focuses on industry cooperation and strives to create greater value for upstream and downstream partners with sincere belief. It not only cooperates with Meifurun, Ningbo Sanyuan, Zhuhai AIA and other products in terms of product layout, but also with Wanpenglanger in terms of new product layout. , Suzhou Jingyun, Hongbo Zhiyuan and others carry out cooperative research and development, and also jointly build a platform with overseas returnee R&D team to carry out exploration of the field of innovative drugs. It also has the largest number of world 500 German Fersenius Cabi and the leading domestic pharmaceutical companies in Guangzhou. Baiyunshan and others have established joint ventures, moving from competition to cooperation with many domestic and foreign counterparts, and sharing the cutting-edge technologies and markets of pharmaceuticals.

The company takes social responsibility as its first mission and actively participates in caring for vulnerable groups. In conjunction with the Shengzhou Red Cross Society, it initiated the establishment of the "Zhejiang Anlikang Leukemia Relief Fund". Some families in need have received assistance; and actively participate in targeted poverty alleviation, Tonglong Miaojia Village, Luojia Township, Youxian County has paired up for assistance; it has also continued to work hard in many aspects such as corporate governance, safe operation, green development, and social affairs, committed to achieving harmony and win-win results, reflecting the responsibilities and feelings of the Anlikang people.

Looking to the future, the company will continue to focus on the pharmaceutical industry, integrate internal and external resources, take the opportunity of listing, increase investment in technical transformation and R&D innovation, adhere to the values ​​of "integrity, passion, professionalism, respect, and cooperation", and "healthy development, industry 100 "Being strong" is the vision to build the company into an innovative international pharmaceutical enterprise with strong comprehensive competitiveness in the industry.